Drugs for acid related disorders - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 2.04 [1.32, 3.14]< 128%3 studies (-/3)0.1 %lownot evaluable highcrucial-
clinical deterioration 2.71 [1.17, 6.30]< 10%1 study (-/1)1.0 %NAnot evaluable important-
mechanical ventilation 2.52 [1.58, 4.01]< 10%2 studies (-/2)0.0 %NAnot evaluable important-
ICU admission 0.98 [0.66, 1.46]< 10%1 study (-/1)53.8 %NAnot evaluable non important-

safety endpoints 00

superinfection 2.37 [1.08, 5.21]< 10%1 study (-/1)1.6 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.